Insulin Delivery Systems: Reducing Barriers to Insulin Therapy and Advancing Diabetes Mellitus Treatment
Section snippets
Barriers to insulin initiation
Anxiety about needles and perceived injection pain is a well-documented barrier to insulin use. Patients with diabetes who require insulin treatment and suffer from profound injection-related anxiety are more likely to experience high levels of diabetes-related distress, psychological issues, and poor adherence to therapy.9 Unfortunately, needle-anxiety is widespread: a study investigating attitudes to injections in 400 young adults visiting a travel clinic found that 21.7% were afraid of
The development of insulin pens
Insulin pens were developed in 1985 as the first alternative to vials and syringes, and fall into 2 main categories: reusable (durable) and disposable (prefilled). Reusable pens require single-use cartridges that are replaced when empty. Disposable pens are prefilled, used, and then discarded. In particular, they offer the advantage of being factory calibrated, so there is no risk of introducing dosing error through reloading problems.17, 18 Multiple daily injection (MDI) regimens can also be
Insulin pumps and continuous subcutaneous insulin infusion
External insulin pumps are highly effective systems capable of providing constant subcutaneous insulin infusion (CSII) delivery. CSII is used in place of MDI, mostly among patients with type 1 diabetes. Only rapid–acting insulin analogues (aspart, glulisine, lispro) or regular human insulins are used in CSII pumps, and doses can be adjusted by the patient to give bolus delivery with food or to provide a low basal level of insulin between meals. A catheter is inserted into the subcutaneous
Inhaled insulin
The lungs are an effective route for insulin delivery, having a large surface area for absorption (100 m2), potential for rapid uptake, and onset of action after inhalation. New developments in asthmatic therapy have seen the production of more powerful inhalers that are able to propel insulin further into the lung, and manufacturers are now able to produce smaller aerosol particles—both of which help to optimize delivery.37 Inhaled insulins are designed to provide a “bolus” or mealtime dose,
Summary
Perceptions of insulin and its delivery have the potential to create strong barriers that limit initiation and intensification of treatment, depriving patients with diabetes of the benefits of improved glycemic control, and increasing the risk for developing future complications. Part of this psychological aversion to insulin may be owing to dislike of syringes. Modern insulin- delivery systems have been developed to be more user friendly, offering simpler, less painful, and more convenient
Author disclosures
The author of this article has disclosed the following industry relationships:
Stephen Brunton, MD, serves on advisory boards for Abbott Laboratories, Amylin Pharmaceuticals Inc., AstraZeneca, and Novo Nordisk A/S.
References (48)
- et al.
Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin dependent diabetes mellitus: a randomized prospective 6-year study
Diabetes Res Clin Pract.
(1995) - et al.
Insulin-treated diabetes patients with fear of self-injecting or fear of self-testing: psychological comorbidity and general well-being
J Psychosom Res.
(2001) Initiating and intensifying insulin therapy in type 2 diabetes mellitus
Am J Med.
(2008)Pharmacokinetic and pharmacodynamics advantages of insulin analogues and premixed insulin analogues over human insulins: impact on efficacy and safety
Am J Med.
(2008)- et al.
Assessment by patients with diabetes mellitus of two insulin pen delivery systems versus a vial and syringe
Clin Ther.
(1998) - et al.
A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus
Clin Ther.
(2003) - et al.
Pain and mechanical injury of human skin following needle insertions
Eur J Pain
(1999) - et al.
FlexPen®: addressing issues of confidence and convenience in insulin delivery
Clin Ther.
(2005) - et al.
Risk of needlestick injuries by injection pens
J Hosp Infect.
(2006) Novel forms of insulin delivery
Endocrinol Metab Clin North Am.
(1997)
Technical risks with subcutaneous insulin infusion
Diabetes Metab.
Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study
Lancet
Treatment satisfaction in type 2 diabetes: a comparison between an inhaled insulin regimen and a subcutaneous insulin regimen
Clin Ther.
A glimpse of the natural history of established type 2 (non-insulin dependent) diabetes mellitus from the spectrum of metabolic and hormonal responses to a mixed meal at the time of diagnosis
Diabetes Res Clin Pract.
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
N Engl J Med.
Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPD33)
Lancet.
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
N Engl J Med.
Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem
Diabetes Care.
UKPDS 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years
BMJ.
Resistance to insulin therapy among patients and providers
Diabetes Care
Fear of injections in young adults: prevalence and associations
Am J Trop Med Hyg.
When oral agents fail: practical barriers to starting insulin
Int J Obes.
Barriers to initiating insulin therapy in patients with type 2 diabetes mellitus in public-sector primary health care centres in Cape Town
S Afr Med J.
Insulin-therapy resistance: another form of insulin resistance in type 2 diabetes
Practical Diabetology
Cited by (45)
Advanced drug delivery systems for treatment of diabetes mellitus
2022, Drug Delivery Systems for Metabolic DisordersMethod to generate a large cohort in-silico for type 1 diabetes
2020, Computer Methods and Programs in BiomedicineCitation Excerpt :The greatest benefit of CSII for the subject is that it can program basal insulin delivery with a basal infusion ratio adjusted to daily life conditions. Another benefit is that the subject can be administered prandial insulin bolus adjusted to carbohydrate (CHOs) intake [34]. Of the 256 subjects, only 18 subjects (same amount of subjects of CO) are chosen to be treated with insulin pump therapy for each generated cohort in order to obtain normoglycemia for a specific daily meal plan.
A qualitative study exploring patients’ experiences regarding insulin pump use
2018, Saudi Pharmaceutical JournalCitation Excerpt :This improved adherence was attributed to the improvement in participants’ satisfaction as a result of the reduced burden of dose tracking and scheduling, and enhanced life flexibility. Studies exploring patients’ perceptions about the advantages of the insulin pump reported more convenience and flexibility, better freedom, ease with meals, and consequently better quality of life (Ritholz et al., 2007; Brunton, 2008; Yilmaz and Oguzhan, 2008; Didangelos and Iliadis, 2011; Reznik et al., 2014). Barnard et al. (2007) also reported feelings of a more ‘normal’ lifestyle among insulin pump users due to freedom from interruptions of insulin injections.
Initiating insulin in patients with type 2 diabetes
2012, CMAJ. Canadian Medical Association JournalCitation Excerpt :Data regarding the effect of different regimens on vascular outcomes, lipid profile and quality of life are limited (see Appendix 8, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.110779/-/DC1). Our review identified 15 randomized trials that compared basal regimens with premixed regimens (Table 2).14,18,30–42 Patients given a premixed regimen were found to have a greater reduction in HbA1c, but they also had greater weight gain and a higher risk of hypoglycemia.
Biomedicine: electrospun nanofibrous hormonal therapies through skin/tissue—a review
2023, International Journal of Polymeric Materials and Polymeric BiomaterialsThe Review of Insulin Pens—Past, Present, and Look to the Future
2022, Frontiers in Endocrinology
Statement of author disclosure: Please see the Author Disclosures section at the end of this article.